Larotrectinib demonstrated activity against 17 oncopathologies

news

Scientists have developed and successfully tested the first oral drug laotrektinib (larotrectinib), which causes a stable therapeutic response among adults and children suffering from various malignant tumors characterized by TRK-fusion proteins. The results of the studies were presented at the annual conference of the American Society of Clinical Oncology, writes MedicalXpress.
It was shown that 76% of patients with advanced malignancies meet the therapy with larotrectinib regardless of age and tumor location,79% of the therapy remained effective throughout the year. The study involved 55 patients (12 children and 43 adults) with advanced or metastatic colorectal cancer, lung cancer, pancreas, thyroid and salivary gland, malignant neoplasms of the gastrointestinal tract, as well as melanoma and sarcoma. The clinical study included only patients with TRK-fused proteins.
Larotrectinib is a selective inhibitor of tropomyosin-receptor kinase (TRK) fusion proteins that are formed by fusion of tumor cells of the TRK gene with other genes. A similar genetic disorder develops in 0.5-1% of the most common malignant neoplasms, but it is characteristic of some rare oncology pathologies: salivary gland cancer, children's fibrosarcoma, juvenile breast cancer.

A source:

Remedium